Fresenius, a global healthcare company, will receive a new €400 million loan from the European Investment Bank (EIB) to strengthen Fresenius’ European research and development (R&D) activities. The financing will be used to support expansion of Fresenius Kabi's manufacturing of medical products and biosimilars in European countries.
The European Investment Bank (EIB) is pleased to announce the appointment of Karl Nehammer as a new Vice-President and Member of its Management Committee, following a decision by the 27 EU Finance Ministers, representing the EIB’s shareholders, the EU Member States.
The European Investment Bank Group approved a total of €15.5 billion in new financing to back business growth and corporate innovation, improve transport and energy connectivity, invest in housing and strengthen water resilience.